Qiagen (NYSE:QGEN) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Qiagen (NYSE:QGEN) released its quarterly earnings data on Wednesday. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.01, Zacks reports. Qiagen had a net margin of 4.73% and a return on equity of 13.43%. Qiagen updated its Q1 2025 guidance to 0.500- EPS and its FY 2025 guidance to 2.280- EPS.

Qiagen Stock Down 3.6 %

Shares of NYSE QGEN traded down $1.51 during mid-day trading on Friday, hitting $40.93. The company had a trading volume of 484,844 shares, compared to its average volume of 1,201,888. Qiagen has a 1-year low of $40.15 and a 1-year high of $49.30. The company has a market capitalization of $9.08 billion, a PE ratio of 102.13, a price-to-earnings-growth ratio of 3.10 and a beta of 0.36. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The business’s 50-day simple moving average is $43.80 and its 200 day simple moving average is $43.25.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group restated a “buy” rating and set a $52.50 target price (up previously from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price target for the company. in a research note on Thursday, October 17th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $46.67 price target (down previously from $48.61) on shares of Qiagen in a research note on Monday, January 6th. UBS Group dropped their price target on Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.84.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.